A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Migraine

Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Migraine

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Jun 2017

At a glance

  • Drugs Galcanezumab (Primary)
  • Indications Migraine
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Arteaus Therapeutics; Eli Lilly
  • Most Recent Events

    • 11 Jun 2017 Results (n=858) of pooled analysis assessing hepatic safety using patient data from three phase 2 trials (NCT02163993 and NCT01625988), presented at the 59th Annual Scientific Meeting of the American Headache Society
    • 28 Apr 2017 Results (n=858) of pooled analysis assessing hepatic safety using patient data from three phase 2 trials (NCT02163993 and NCT01625988), presented at the 69th Annual Meeting of the American Academy of Neurology
    • 20 Apr 2017 Results of a Post-Hoc Analysis from this trial will be presented at the American Academy of Neurology (AAN) annual meeting 2017, as reported in an Eli Lilly and Company media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top